A pan-cancer analysis confirms PTPN11's potential as a prognostic and immunological biomarker.

Biomarkers, Tumor / genetics Endothelial Cells / metabolism Head and Neck Neoplasms Humans Lung Neoplasms / genetics Prognosis Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics
PTPN11 immune infiltration pan-cancer phosphorylation prognosis

Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
08 07 2022
Historique:
received: 29 03 2022
accepted: 01 07 2022
pubmed: 9 7 2022
medline: 26 7 2022
entrez: 8 7 2022
Statut: ppublish

Résumé

Protein tyrosine phosphatase, non-receptor type 11 (PTPN11) is a multifunctional tyrosine phosphatase and has a significant part in many types of tumors. As of yet, neither the expression profile of PTPN11 nor its significance in pan-cancer diagnosis has been clarified. With the assistance of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we have comprehensively mapped the expression profiles, prognostic significance, genetic alteration, phosphorylation status, infiltration of immune cells, and functional properties of PTPN11 in 33 human tumors. There was an inconsistent expression of

Identifiants

DOI: 10.18632/aging.204171 PMID: 35802774 PMC: PMC9320542
pubmed: 35802774
pii: 204171
doi: 10.18632/aging.204171
pmc: PMC9320542
doi:

Substances chimiques

Biomarkers, Tumor 0
PTPN11 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 11 EC 3.1.3.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5590-5610

Références

Leukemia. 2016 Oct;30(10):2094-2097
pubmed: 27256702
Mol Cancer Res. 2013 Jun;11(6):651-64
pubmed: 23512980
Cell Immunol. 2019 Sep;343:103729
pubmed: 29397066
Nat Rev Cancer. 2016 Jan;16(1):35-42
pubmed: 26667849
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1531-9
pubmed: 21803945
Mol Carcinog. 2018 May;57(5):619-628
pubmed: 29323748
Exp Hematol. 2008 Oct;36(10):1285-96
pubmed: 18640765
Blood. 2007 Feb 1;109(3):862-7
pubmed: 17053061
Oncogene. 2020 Jan;39(4):786-800
pubmed: 31548613
Trends Immunol. 2019 Apr;40(4):310-327
pubmed: 30890304
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
Nature. 2007 Mar 8;446(7132):153-8
pubmed: 17344846
Eur J Cancer. 2020 May;131:40-50
pubmed: 32278982
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Oncogene. 2008 Jun 5;27(25):3508-15
pubmed: 18223690
Nat Commun. 2021 Nov 2;12(1):6310
pubmed: 34728626
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Res. 2017 Apr 1;77(7):1510-1541
pubmed: 28373404
Cancer Treat Rev. 2020 Jun;86:102024
pubmed: 32388292
Cancer Cell. 2011 May 17;19(5):629-39
pubmed: 21575863
Science. 1993 Mar 12;259(5101):1607-11
pubmed: 8096088
Nat Med. 2012 Mar 04;18(4):529-37
pubmed: 22388088
Nature. 2013 Jul 25;499(7459):491-5
pubmed: 23863940
Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H231-43
pubmed: 22058153
Cancer Res. 2007 May 1;67(9):4278-86
pubmed: 17483340
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Methods Mol Biol. 2016;1418:93-110
pubmed: 27008011
Pharmacol Res. 2020 Feb;152:104595
pubmed: 31838080
Am J Cancer Res. 2019 Sep 01;9(9):1957-1969
pubmed: 31598397
J Med Chem. 2020 Oct 22;63(20):11368-11396
pubmed: 32460492
Cell. 2018 Apr 5;173(2):530
pubmed: 29625059
Blood. 2010 Nov 4;116(18):3611-21
pubmed: 20651068
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
J Cell Mol Med. 2015 Sep;19(9):2075-83
pubmed: 26088100
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Hepatology. 2017 May;65(5):1566-1580
pubmed: 28059452
Adv Exp Med Biol. 2020;1234:71-86
pubmed: 32040856
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Biochem Soc Trans. 2016 Apr 15;44(2):333-41
pubmed: 27068937
Curr Top Microbiol Immunol. 2011;344:1-24
pubmed: 20512556
Blood. 2019 Dec 19;134(25):2304-2317
pubmed: 31562133
Cancer Lett. 2017 Feb 28;387:61-68
pubmed: 26845449
Mol Cancer Res. 2019 Feb;17(2):583-593
pubmed: 30355677
Pharmacol Ther. 2022 Feb;230:107966
pubmed: 34403682
Mol Cell. 2001 Oct;8(4):759-69
pubmed: 11684012
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4257-62
pubmed: 22371576
Oncogene. 2019 Mar;38(13):2275-2290
pubmed: 30467378
Acta Pharm Sin B. 2019 Mar;9(2):304-315
pubmed: 30972278

Auteurs

Yapeng Cao (Y)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi 710061, China.

Haixia Duan (H)

Department of Reproduction Gynecology, Northwest Women and Children's Hospital, Xi'an, Shaanxi 710061, China.

Ailing Su (A)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi 710061, China.

Liran Xu (L)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi 710061, China.

Baochang Lai (B)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi 710061, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Diagnostic › Pronostic › A pan-cancer analysis confirms PTPN11's...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein Tyrosine Phosphatases › SH2 Domain-Containing Protein Tyrosine Phosphatases › Protein Tyrosine Phosphatase, Non-Receptor Type 11 › A pan-cancer analysis confirms PTPN11's...